Does Intranasal Insulin Reach Critical Brain Areas Linked to Memory and Cognition?
Insulin delivered via nasal spray in this first-in-human PET imaging study was observed in 11 key brain areas relevant to cognitive decline, validating a new research avenue.
FDA Accepts Gepotidacin for Priority Review for the Treatment of Uncomplicated Urogenital Gonorrhea
FDA accepts priority review of gepotidacin for uncomplicated urogenital gonorrhea, with phase 3 data showing non-inferiority to standard injectable therapy.
Investigational Oral IL-23 Receptor Antagonist Icotrokinra Improves Skin Clearance in Psoriasis in Phase 3 Study
The oral peptide that selectively targets IL-23 offers a novel approach to quelling the inflammatory process that underlies plaque psoriasis.
GLP-1 RAs Beat Metformin for Dementia Prevention in T2D: Daily Dose
Your daily dose of the clinical news you may have missed.
Are the GLP-1 Agonists "Forever Drugs?" It's an Open Question, According to Jonathan Bonnet, MD, MPH
The obesity and lifestyle medicine specialist says while research on the question continues, a focus on optimizing nutritional health during treatment is essential.
The TikTok Doc Is In: But Will Your Patient Trust the Diagnosis?
Health information permeates social media platforms exposing Americans to advice, even when they don't want it. The good news? Not many trust it!
How Physicians Can Strengthen Vaccine Confidence During National Immunization Awareness Month
Board-certified family physician Sarah Sams, MD, urges physicians to actively engage their communities to build vaccine confidence and combat misinformation.
Excess Intake of Ultraprocessed Foods is Tied to Higher Cardiometabolic Risk, AHA Advisory Panel Says
The Advisory Panel laid out 4 priority actions for clinicians, policy makers, and industry.
Novel Plasma Assays That Selectively Detect Tau Characteristics Will Refine Clinical Study of Alzheimer Disease
The 2 new plasma assays to enhance Alzheimer’s disease research will support disease staging, predicting disease progression, and monitoring treatment outcome.
FDA Approves Finerenone for Treatment of Heart Failure With LVEF ≥40%: Daily Dose
The Weekly Dose: Pediatric Vaccine Safety, Atopic Dermatitis, Dementia Risk, and Maternal Depression
Insights on atopic dermatitis treatment preferences, the safety of childhood vaccines, maternal depression’s effect on parenting, and more.
GLP-1 Medications Need a Permanent Place in Primary Care, Says Obesity Medicine Specialist
Jonathan Bonnet, MD, MPH, encourages primary care clinicians to embrace GLP-1 therapy where appropriate to stem multiple risk factors for downstream chronic diseases.
Use of Weight-Loss Drugs Increased Among US Adolescents After AAP Guideline Release
New data shows pediatric pharmacotherapy prescribing rose but remained infrequent, while nutrition counseling rates changed minimally.
Lilly's Oral GLP-1 Agonist Orforglipron Linked to Weight Reduction of 12.4% in Pivotal Phase 3 Trial
The investigational daily oral GLP-1 RA met the primary endpoint for body weight reduction at 72 weeks and also improved a range of cardiovascular risk factors.
Reframing Vaccines as Innovation: A Strategy to Rebuild Patient Trust in Primary Care
Infectious disease physician Amesh Adalja, MD, explains how PCPs can reframe vaccines as health technology to boost confidence and counter hesitancy.
Study Sheds Light on Public Perception of Physicians Who Use AI: Daily Dose
Why Should Primary Care Clinicians Shift to AI-Powered Cognitive Assessment? Experts Explain
Fremanezumab Label Expanded for Treatment of Episodic Migraine in Children Aged 6 to 17 Years
Fremanezumab is now the only CGRP antagonist indicated for prevention of migraine in adults and preventive treatment of episodic migraine in pediatric patients.
11 US Vaccine Policy Updates: How Will They Affect Your Practice?
Since his Senate approval as head of HHS in February, RFK Jr has enacted and/or proposed seismic changes to US vaccine policy that will impact your daily care of patients.
Investigational Antidepressant BH-200 Shows Benefit in Phase 2b Trial for MDD
The vasopressin V1b antagonist reduced depressive symptoms, with greater effects in genetically-selected patients using a precision psychiatry approach.
.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "How Physicians Can Strengthen Vaccine Confidence During National Immunization Awareness Month")
.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Reframing Vaccines as Innovation: A Strategy to Rebuild Patient Trust in Primary Care")
